Evidence map›Paper›PMID 40265067›Full record

ArticleFrontiers in public health2025

SARS-CoV-2 genomic surveillance using self-collected saliva specimens during occupational testing programs.

Andrew T Schnaubelt, David M Brett-Major, Janet Williamson, Bailey Barcal, Julie Carstens, Ashley Peer, Michael Wiley, M Jana Broadhurst

Abstract read
In one paragraph

Article in Frontiers in public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Andrew T Schnaubelt *Department of Pathology, Microbiology, and Immunology, College of Medicine, University of Nebraska Medical Center, Omaha, NE, United States.
David M Brett-Major *Department of Epidemiology, College of Public Health, University of Nebraska Medical Center, Omaha, NE, United States.
Janet WilliamsonDepartment of Pathology, Microbiology, and Immunology, College of Medicine, University of Nebraska Medical Center, Omaha, NE, United States.
Bailey BarcalDepartment of Pathology, Microbiology, and Immunology, College of Medicine, University of Nebraska Medical Center, Omaha, NE, United States.
Julie CarstensDepartment of Pathology, Microbiology, and Immunology, College of Medicine, University of Nebraska Medical Center, Omaha, NE, United States.
Ashley PeerDepartment of Pathology, Microbiology, and Immunology, College of Medicine, University of Nebraska Medical Center, Omaha, NE, United States.
Michael WileyDepartment of Pathology, Microbiology, and Immunology, College of Medicine, University of Nebraska Medical Center, Omaha, NE, United States.
M Jana BroadhurstDepartment of Pathology, Microbiology, and Immunology, College of Medicine, University of Nebraska Medical Center, Omaha, NE, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Continually emerging SARS-CoV-2 variants pose challenges to clinical and public health interventions, necessitating sustainable approaches to real-time variant monitoring. This case study describes an innovative SARS-CoV-2 screening and surveillance program that demonstrates the utility of sequencing-based variant monitoring using self-collected saliva specimens. We conducted saliva-based SARS-CoV-2 screening in occupational settings in Omaha, Nebraska from December 2021 through November 2022. 8,372 saliva specimens collected from 1,480 participants were tested for SARS-CoV-2 RNA by extraction-free PCR, with 334 positive samples referred for whole-genome sequencing analysis. Program utilization, quality metrics, and sequencing outputs were compared across sites. Specimen quality was high across program settings, demonstrating the suitability of self-collected saliva specimens for PCR and genomic surveillance testing. Virus RNA sequencing successfully determined the variant strain in 83 and 67% of SARS-CoV-2-positive saliva samples collected in two program settings, demonstrating the successful integration of SARS-CoV-2 sequencing for variant determination into screening programs in occupational settings using self-collected saliva with an extraction-free qRT-PCR testing method. We further demonstrate that the sensitivity and efficiency of variant analysis is dependent on the PCR cycle threshold (Ct) cutoff of the diagnostic assay virus gene target. Use of an optimized Ct value cutoff for sequencing referral is recommended. Community-based saliva testing programs can be utilized to enhance variant monitoring, and could be considered in the risk identification of other respiratory infections. This approach offers the advantages of a non-invasive specimen collection, no need for supervised collection by a healthcare worker, supply chain resiliency, distributable access, and scalability.

Indexed as

COVID-19SalivaSARS-CoV-2Specimen HandlingAdultCOVID-19 Nucleic Acid TestingFemaleHumansMaleMass ScreeningMiddle AgedNebraskaRNA, ViralWhole Genome SequencingRNA, ViralCOVID-19genome sequencingsalivaSARS-CoV-2surveillancevariant

Identifiers

PMID40265067
PMCPMC12011812

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.